Subject Satisfaction with Trifarotene 50 μg/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series
Abstract There is a paucity of literature covering patient-reported outcomes of treatments for truncal acne. Trifarotene 50 μg/g cream is a novel retinoid molecule approved for once-daily topical treatment of facial and truncal acne vulgaris. As physicians are starting to gain real-world experience...
Saved in:
Main Authors: | Sandra M. Johnson (Author), Rajeev Chavda (Author), Janet C. DuBois (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
by: Brumfiel CM, et al.
Published: (2021) -
Impact of facial and truncal acne on quality of life: A multi-country population-based surveyCapsule Summary
by: Jerry Tan, MD, et al.
Published: (2021) -
Trifarotene: A Novel Therapeutic Option for Acne
by: Piyu Parth Naik
Published: (2022) -
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study
by: Stephen Schleicher, et al.
Published: (2023) -
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study
by: Stephen Schleicher, et al.
Published: (2024)